The lead investigator will give an important update on the ALS phase I trial on Friday, May 17 that will have meaningful efficacy data on eight patients and safety data on fourteen.
http://seekingalpha.com/article/1439961-neuralstem-update-on-als-trial-could-be-a-catalyst-for-the-stock?source=feed
http://seekingalpha.com/article/1439961-neuralstem-update-on-als-trial-could-be-a-catalyst-for-the-stock?source=feed
No comments:
Post a Comment